InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.

References

Next >

Home‍ ‍Screening‍ ‍MRD + Monitoring‍ ‍‍ ‍Treatment Selection

Methylation-enhanced ALK fusion detection identified 31% of patients missed by genomics alone¹

          
        ALK fusion patients detected by Guardant360 Liquid CDx Test*
      
            Genomic-only Detection
          
            Methylation-enhanced Detection†
          
            100% of genomic-positive patients identified with epigenomics
          
            +
          
              31%
            
              of patients missed by

              genomics alone had an

              ALK fusion identified by

              methylation-based analysis
            
        Find more ALK fusion patients with the

        only liquid profiling test with epigenomics1,3–6

*Statement applies to Guardant360 Liquid LDT as reported in a professional service report, which is part of Guardant360 Liquid CDx. The professional service report is not reviewed nor approved by the FDA. #1 liquid biopsy statement is based on stated brand utilization from a market research survey.